The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein matrix devices. Furthermore, the present invention relates to protein matrix materials and devices made by forming a film comprising one or more biodegradable protein materials, one or more biocompatible solvents and optionally one or more pharmacologically active agents. The film is then partially dried, rolled or otherwise shaped, and then compressed to form the desired protein matrix device.

Protein matrix materials, devices and methods of making and using thereof

Methods are also provided for preparing stabilized formulations of whole antibody crystals or antibody fragment crystals using pharmaceutical ingredients or excipients and optionally encapsulating the crystals or crystal formulations in a polymeric carrier to produce compositions and using such protein crystals for biomedical applications, including delivery of therapeutic proteins and vaccines.

Crystals of whole antibodies and fragments thereof and methods for making and using them

The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically not effective carrier of not-inhalable particle size and a finely divided pharmaceutical substance of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. One of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.

Dry powder for inhalation

Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on said substrate, wherein said coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within said coating and on said substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of said medical device in the body of said subject a portion of said pharmaceutical agent and/or active biological agent is delivered at said intervention site along with at least a portion of said polymer and/or a at least a portion of said pharmaceutical carrying agents.

Drug delivery medical device

Methods for forming sustained release microspheres and the products produced thereby are provided. The microspheres have a smooth surface that includes a plurality of channel openings that are less than 1000 angstroms in diameter.

Sustained release microspheres

Microparticles formed by mixing a macromolecule with a polymer at a pH near the isoelectric point of the macromolecule and incubating the mixture in the presence of an energy source for a predetermined length of time. The microparticles are composed of homogeneously distributed, intertwined macromolecule and polymer. Each microparticle allows aqueous fluids to enter and allows solubilized macromolecule and polymer to exit the microparticle and may be formulated to provide a sustained release of macromolecule and polymer from the interior of the microparticle when placed in an appropriate aqueous medium, such as under physiological conditions. Methods of production and methods of use for research, diagnostics and therapeutics are provided.

Macromolecular microparticles and methods of production and use

***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***Macromolecular microparticles and methods of production and use

Microsphären mit verzögerter wirkstoffabgabe

Microesfera que comprende: (1) una proteina portadora; (2) un polimero soluble en agua; (3) un primer agente complejante que es un polisacarido polianionico y (4) un segundo agente complejante que es un cation metalico divalente seleccionado de entre el grupo consistente en calcio y magnesio caracterizada porque, excluyendo una microesfera la proteina portadora es albumina, el polimero soluble en agua es polietilenglicol (PEG), polivinilpirrolidona (PVP), mezclas de ambos, almidon o hidroxietilalmidon; el primer agente complejante que es un polisacarido polianionico es sulfato de dextrano, heparina o sulfato de heparina; y el segundo agente complejante que es un cation metalico divalente es calcio o magnesio

Charles D. Blizzard

Papers

Macromolecular microparticles and methods of production and use

Sustained release microspheres

WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LISTMacromolecular microparticles and methods of production and use

Microsphären mit verzögerter wirkstoffabgabe

Microesferas de liberacion prolongada.